|
TechInvention’s GCMC to serve entire cycle of vaccine development: Expert
|
|
Shardul Nautiyal, Mumbai
March 30 , 2024
|
|
|
TechInvention’s Global Collaborative Centre for Medical Countermeasures (GCMC) in Navi Mumbai is poised to serve the entire cycle of vaccine development, from strain to supply, biotherapeutics and diagnostics for both human and veterinary segments, while ensuring sustainable manufacturing, said Syed Ahmed, director and CEO of TechInvention.
He added that this initiative aligns with the One Health approach, emphasizing the interconnection between human, animal, and environmental health.
Started in 2016, TechInvention does project planning, project feasibility, technology licensing, WHO prequalification (PQ) support, design engineering, regulatory affairs, clinical research, and intellectual property (IP) support to pharmaceutical and biotech companies, governments, and investors.
The GCMC facility in Navi Mumbai will serve the needs of both public and private organizations, such as academic institutes, start-ups, MSMEs, and R&D organizations, to provide a comprehensive ecosystem, facilitating the transition from R&D to GMP-scale production for pre-clinical/clinical batches with required regulatory approvals.
Ahmed said that the current challenges posed in biologics equity arise from the disparity in translational research dissemination from the centres of excellence to the regional manufacturing ‘hub and spoke’ model setups. GCMC would be the needed intervention, strengthening the hubs by providing ‘scaled-up’, regulatory-approved, cost-effective, and free of IP infringement biosolutions sourced from both indigenous research and centres of excellence worldwide.
TechInvention's multifaceted approach in human and veterinary segment encompass a wide array of initiatives, ranging from research and development to strategic and technical advisory and also ensuring global access to critical vaccines, diagnostics and biotherapeutics. Of particular note is TechInvention's proactive stance in corporate social responsibility, highlighted by its initiative to establish a Biosafety Level 2 (BSL2) facility for research and development. This initiative underscores the company's commitment to fostering innovation and research in critical areas of healthcare.
Furthermore, TechInvention's strategic partnerships and in-licensing agreements with global pharmaceutical and biotech companies enable the swift introduction of vital vaccines to India. This also ensures meticulous management of clinical trials, regulatory compliance, and intellectual property rights (IPR).
TechInvention's broad portfolio of services includes strategic and technical advisory, providing invaluable expertise in setting up vaccine infrastructure in low -middle income countries (LMICs). Through these endeavours, TechInvention solidifies its position as a trailblazer in the field of infectious disease interventions, driving forward the mission of a healthier world for all.
TechInvention GCMC believes in making global health equity a reality. GCMC has been acknowledged for its global significance at the 2nd World Local Production Forum in The Hague between November 6 and 8, 2023, organized by the World Health Organisation (WHO). The objective of GCMC is well aligned to WHO’s call to action, CEPI’s 100 days mission, India’s National Biotechnology Development Strategy (2020-2025), and other global key initiatives.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|